Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUDAFED 12 HOUR vs ADVIL CONGESTION RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Temporary relief of nasal congestion due to common cold, hay fever, or other upper respiratory allergies
temporary relief of nasal congestion,sinus pressure,headache,fever,minor aches and pains associated with common cold or flu
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (Cr Cl <30 m L/min); shorter in children (3-4 hours)
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Hepatic metabolism via N-demethylation to active metabolite; primarily excreted unchanged in urine
ibuprofen: primarily hepatic via CYP2C9; phenylephrine: primarily hepatic via monoamine oxidase (MAO) and sulfation
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
50-60% bound (primarily to albumin and alpha-1-acid glycoprotein)
Ibuprofen: >99% bound to albumin. Pseudoephedrine: 20-30% bound to albumin.
2.6-3.5 L/kg in adults; indicates extensive tissue distribution (higher than total body water)
Ibuprofen: 0.1-0.2 L/kg (low, reflects high protein binding). Pseudoephedrine: 2.6-3.5 L/kg (extensive tissue distribution).
Oral: 90-100% (immediate-release); sustained-release: approximately 95%
Oral: Ibuprofen ~80-100% (high), Pseudoephedrine ~100% (high).
GFR 30-50 m L/min: reduce dose to 60 mg every 12 hours. GFR <30 m L/min: use is contraindicated.
Avoid use if Cr Cl <30 m L/min. For Cr Cl 30-59 m L/min, use lowest effective dose and shortest duration.
Child-Pugh A: no adjustment. Child-Pugh B or C: consider reducing dose or extending interval due to reduced clearance; specific guidelines not established.
Avoid use in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and at the lowest effective dose.
Children 6-12 years: 60 mg orally every 12 hours; maximum 120 mg/day. Children <6 years: not recommended.
Not recommended in children under 12 years of age due to phenylephrine component. For children 12 years and older, same as adult dosing.
Start at lower end of dosing range (60 mg every 12 hours); monitor for CNS stimulation, hypertension, and urinary retention.
Start at the low end of dosing range; avoid use in patients 65 years and older if possible due to increased risk of adverse effects; if necessary, use lowest effective dose for shortest duration.
None
ibuprofen carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal, and for serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines
Cardiovascular effects: hypertension, palpitations, tachycardia,CNS stimulation: insomnia, nervousness, dizziness,Exacerbation of narrow-angle glaucoma,Exacerbation of prostatic hypertrophy/urinary retention,Diabetes mellitus: may increase blood glucose
cardiovascular risk,gastrointestinal risk,renal effects,avoid concomitant use of other NSAIDs,hypertension,hyperthyroidism,diabetes,heart disease,use with MAOIs may cause hypertensive crisis
Severe hypertension,Coronary artery disease,Concurrent or recent (within 14 days) MAOI therapy,Narrow-angle glaucoma,Urinary retention
hypersensitivity to ibuprofen, phenylephrine, or any component,history of asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs,perioperative pain in setting of coronary artery bypass graft (CABG) surgery,severe hypertension,severe coronary artery disease,use of MAOIs or within 14 days of stopping MAOIs
Avoid caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase central nervous system stimulation and exacerbate side effects like nervousness and insomnia. High-tyramine foods (aged cheeses, cured meats, fermented products) should be limited in patients taking MAOIs, but no direct interaction with pseudoephedrine alone. Alcohol may increase dizziness and should be avoided.
Avoid alcohol consumption due to increased risk of GI bleeding and liver damage. No specific food interactions; take with food or milk to reduce stomach upset. Caffeine may exacerbate pseudoephedrine's stimulant effects; limit caffeine intake.
Category C. First trimester: Possible risk of gastroschisis (limited data). Second and third trimesters: Uterine vasoconstriction, reduced placental perfusion; avoid due to risk of fetal hypoxia, tachycardia, and intrauterine growth restriction. No adequate well-controlled human studies.
First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and premature ductus arteriosus constriction. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Phenylephrine: Limited human data; animal studies show fetal abnormalities at high doses; avoid in first trimester due to potential vascular disruption.
Pseudoephedrine is excreted into breast milk (M/P ratio approximately 2.0-3.5). Use with caution: may reduce milk production and cause irritability in infants. Highest risk in preterm infants or those with impaired renal function. Avoid if possible; use lowest effective dose if necessary.
Ibuprofen: Excreted into breast milk in low amounts (M/P ratio ~0.07). Compatible with breastfeeding; minimal infant exposure. Phenylephrine: Not known if excreted in breast milk; M/P ratio unknown. Avoid due to potential for infant hypertension and irritability. Alternative decongestants preferred.
No specific dose adjustment recommended, but use is generally avoided in pregnancy. If necessary, use immediate-release formulations at lowest effective dose for shortest duration. Extended-release formulations (e.g., 12-hour) are not recommended due to prolonged systemic exposure. Pharmacokinetic changes in pregnancy (increased volume of distribution, reduced plasma concentrations) may necessitate more frequent dosing, but safety data insufficient; avoid.
Pharmacokinetic changes in pregnancy: Increased volume of distribution and clearance for ibuprofen may require higher doses, but avoid due to fetal risks. No standard dose adjustment recommended; use lowest effective dose for shortest duration. Phenylephrine: No specific dosing adjustments in pregnancy; avoid use due to limited safety data.
Pseudoephedrine is a sympathomimetic amine that causes vasoconstriction; avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Extended-release formulation provides 12-hour symptom relief. Use with caution in patients with diabetes, hyperthyroidism, or prostatic hyperplasia. Monitor for nervousness, dizziness, or insomnia. Not recommended for use with MAOIs or within 14 days of stopping MAOIs.
Advil Congestion Relief combines ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen can cause nephrotoxicity; pseudoephedrine can elevate blood pressure and heart rate. Avoid in patients with uncontrolled hypertension, severe CAD, or MAOI use within 14 days. Use with caution in elderly due to increased risk of GI bleeding and CNS effects. Not recommended for children under 12 years.
Do not crush or chew the tablet; swallow whole with water.,Take with food or milk if stomach upset occurs.,Avoid taking within 4-5 hours of bedtime to prevent insomnia.,Do not exceed one tablet every 12 hours; maximum 2 tablets in 24 hours.,Discontinue and consult doctor if symptoms persist beyond 7 days or are accompanied by fever.,Avoid using other medications containing pseudoephedrine or other decongestants.,Do not use if you have high blood pressure, heart disease, or are taking MAOIs.
Do not take more than directed; do not use with other products containing ibuprofen or other NSAIDs (e.g., naproxen, aspirin) due to increased risk of stomach bleeding.,Avoid alcohol while taking this medication to reduce the risk of stomach irritation and bleeding.,Pseudoephedrine may cause insomnia, nervousness, or dizziness; take the last dose at least 4-6 hours before bedtime.,Stop use and consult a doctor if symptoms persist after 5 days (fever >3 days), if new symptoms appear, or if you experience signs of stomach bleeding (black/bloody stools, vomit with blood/coffee-grounds).,Do not use if you have heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty urinating due to an enlarged prostate unless directed by a doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUDAFED 12 HOUR vs ADVIL CONGESTION RELIEF, answered by our medical review team.
SUDAFED 12 HOUR is a Decongestant that works by Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.. ADVIL CONGESTION RELIEF is a NSAID/Decongestant Combination that works by ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUDAFED 12 HOUR and ADVIL CONGESTION RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUDAFED 12 HOUR is: 120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.. The standard adult dose of ADVIL CONGESTION RELIEF is: 1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUDAFED 12 HOUR and ADVIL CONGESTION RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUDAFED 12 HOUR is classified as Category C. Category C. First trimester: Possible risk of gastroschisis (limited data). Second and third trimesters: Uterine vasoconstriction, reduced placental perfusion; avoid due to risk of. ADVIL CONGESTION RELIEF is classified as Category C. First trimester: Avoid due to potential increased risk of cardiac defects and gastroschisis from NSAIDs. Second trimester: Use with caution; ibuprofen may cause oligohydramnios and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.